Medikra ^{Filed Terms, NYSE American: MDKR}

Medikra is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical-grade botanical therapeutics. We advance plant-derived bioactive ingredients into regulated medicines by integrating proprietary botanical extraction, analytical standardization, preclinical and clinical development, and multi-omics (e.g. proteomics and transcriptomics) analysis. Through our wholly owned Malaysian subsidiary, Medika Natura Sdn. Bhd., we have established an end-to-end development platform that bridges traditional botanical knowledge with modern biomedical science, regulatory requirements, and scalable manufacturing. Our lead product candidate, SKF7®, is a patented standardized extract of Labisia pumila, a medicinal plant indigenous to Malaysia, under development for the treatment of abdominal obesity and metabolic syndrome. SKF7® has been evaluated in multicenter, randomized, placebo-controlled Phase I and Phase II clinical trials conducted in Malaysia, Indonesia, and India. Our therapeutic focus extends beyond obesity to include women’s health, chronic inflammation, and oncology, areas where current treatments may be limited by efficacy, safety, or tolerability. We do not position our work as alternative medicine. Rather, we aim to advance evidence-based botanical therapeutics that are developed in alignment with international regulatory standards.